Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia.

NCT03701399 is registered in ClinicalTrials.gov with Biohaven Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03701399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03701399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia.
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 8, 2019
Completion date
August 31, 2026
Enrollment
299 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

spinocerebellar ataxia type 1, spinocerebellar ataxia type 10, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, spinocerebellar ataxia type 6, spinocerebellar ataxia type 7, spinocerebellar ataxia type 8, spinocerebellar ataxias